Pricing and market access (P&MA) are key issues for the pharma industry as healthcare budgets continue to tighten and the value of innovative drugs, particularly in areas of high unmet need
AbbVie is preparing to file for accelerated approval of telisotuzumab vedotin (Teliso-V) as a treatment for some patients with lung cancer after the drug hit the mark in a
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio